Atsushi Yoshida1, Naoki Hayashi1, Koyu Suzuki2, Masafumi Takimoto3, Seigo Nakamura1,4, Hideko Yamauchi1. 1. Department of Breast Surgical Oncology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. 2. Department of Diagnostic Pathology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. 3. Department of Pathology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan. 4. Department of Breast Surgical Oncology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan.
Abstract
BACKGROUND: We aimed to assess change in HER2 status after neoadjuvant chemotherapy (NAC) in patients with primary breast cancer and the prognostic impact of such changes. PATIENTS AND METHODS: The study comprised 588 patients with a non-pathologic complete response who received anthracycline and/or taxane-based regimens in NAC setting. HER2 status was assessed before NAC and in residual invasive tumor of the surgical specimens. The associations between the change in HER2 status and clinicopathological factors were assessed. RESULTS: Before NAC, 489 (83%) of the 588 patients had HER2-negative tumors and 99 patients (17%) had HER2-positive tumors. Eleven (2.2%) of the HER2-negative tumors changed to HER2-positive, while 33 (33%) of the HER2-positive tumors changed to HER2-negative. ER and PR-positivity before NAC were associated with loss of HER2-positivity, whereas receiving trastuzumab was not. In terms of disease-free survival, there was no difference between patients with and those without change in HER2 status after NAC in either the patients with HER2-negative tumors (P = 0.26) or with HER2-positive tumors before NAC (P = 0.23). CONCLUSION: Our results showed that changes in HER2 status did not affect patients' prognosis. Further studies are needed to determine whether HER2-targeting agents can be omitted when loss of HER2-positivity is confirmed after NAC.
BACKGROUND: We aimed to assess change in HER2 status after neoadjuvant chemotherapy (NAC) in patients with primary breast cancer and the prognostic impact of such changes. PATIENTS AND METHODS: The study comprised 588 patients with a non-pathologic complete response who received anthracycline and/or taxane-based regimens in NAC setting. HER2 status was assessed before NAC and in residual invasive tumor of the surgical specimens. The associations between the change in HER2 status and clinicopathological factors were assessed. RESULTS: Before NAC, 489 (83%) of the 588 patients had HER2-negative tumors and 99 patients (17%) had HER2-positive tumors. Eleven (2.2%) of the HER2-negative tumors changed to HER2-positive, while 33 (33%) of the HER2-positive tumors changed to HER2-negative. ER and PR-positivity before NAC were associated with loss of HER2-positivity, whereas receiving trastuzumab was not. In terms of disease-free survival, there was no difference between patients with and those without change in HER2 status after NAC in either the patients with HER2-negative tumors (P = 0.26) or with HER2-positive tumors before NAC (P = 0.23). CONCLUSION: Our results showed that changes in HER2 status did not affect patients' prognosis. Further studies are needed to determine whether HER2-targeting agents can be omitted when loss of HER2-positivity is confirmed after NAC.
Authors: Jean Schneider; Hyouk Jin Lee; Seok Jin Nam; Soo Jung Lee; Jin Hyang Jung; Sung Hoo Jung; Seung Taek Lim; Ye Won Jeon; Hongki Gwak Journal: J Breast Cancer Date: 2020-05-12 Impact factor: 3.588
Authors: Gabriela Candás; Alejandra García; María Delfina Ocampo; Ernesto Korbenfeld; H Daniel Vuoto; Juan Isetta; Lucas Cogorno; Agustina González Zimmermann; Marca Sigal; Santiago Acevedo; Julia Berwart; Martín Naveira; Agustina Bemi; Juan Luis Uriburu Journal: Ecancermedicalscience Date: 2021-01-05
Authors: Allen Li; Jamie M Keck; Swapnil Parmar; Janice Patterson; Marilyne Labrie; Allison L Creason; Brett E Johnson; Molly Downey; George Thomas; Carol Beadling; Laura M Heiser; Annette Kolodzie; Alexander R Guimaraes; Christopher L Corless; Joe W Gray; Gordon B Mills; Raymond C Bergan; Zahi I Mitri Journal: NPJ Precis Oncol Date: 2021-03-26